Aquestive Therapeutics (AQST) Institutional Ownership

32.45% of Aquestive Therapeutics' stock is owned by institutional investors. Learn more on AQST's institutional investor holdings.

Of the 145 institutional investors that purchased Aquestive Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Federated Hermes Inc. ($2.03M), Bank of America Corp DE ($1.82M), Vanguard Group Inc. ($1.42M), State Street Corp ($1.37M), BNP Paribas Financial Markets ($1.18M), Pale Fire Capital SE ($1.15M), and Wells Fargo & Company MN ($1.08M).

Institutional investors have bought a total of 21,496,166 shares in the last 24 months. This purchase volume represents approximately $119.22M in transactions.

Of the 35 institutional investors that sold Aquestive Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Perceptive Advisors LLC ($4.55M), Millennium Management LLC ($1.69M), Blue Owl Capital Holdings LP ($725K), Royal Bank of Canada ($350.98K), Walleye Capital LLC ($217.46K), Nuveen LLC ($180.60K), and Financial Engines Advisors L.L.C. ($176.93K).

Institutional investors have sold a total of 8,811,115 shares in the last 24 months. This volume of shares sold represents approximately $49.12M in transactions.